Inhibitex to Present at Three Upcoming Conferences

Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral compounds at the following three conferences:

-- Stifel Nicolaus Healthcare Conference, on Thursday, September 16, 2010 at 8:00 am EDT. The conference is being held at The Four Seasons Hotel in Boston, Massachusetts. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at www.inhibitex.com. Shortly following the live webcast a replay will also be available on the Company website.

-- JMP Securities Fifth Annul Healthcare Conference, on Tuesday, September 28, 2010 at 2:30 pm EDT. The conference is being held at The New York Palace Hotel in New York, New York. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at www.inhibitex.com.

-- Cantor Catalyst Conference, on Wednesday, September 29, 2010. The conference is being held at The Le Parker Meridien in New York, New York.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development, for the treatment of shingles, INX-189, a nucleotide polymerase inhibitor for the treatment of chronic hepatitis C infections currently in a Phase I study, and a staphylococcal vaccine based on its proprietary MSCRAMM protein platform that is partnered with Pfizer and currently in a Phase I study.

For additional information about the Company, please visit www.inhibitex.com.

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.

Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024